Partner with us

Contact us

Work with Absci

partner-work-img

Absci is proud to partner with leaders across pharma, tech, and academia to develop differentiated biologics against challenging targets using generative AI.

Drug creation partnerships

Our process
our-process1224
Our process
our-process1224
  • Design novel therapeutics to challenging targets
  • Create millions of potential leads from novel or validated targets
  • Design better biologics and unlock differentiated biology together with epitope landscaping and optimized epitope interaction
  • Rapidly refine our designs with multiparametric AI lead optimization for enhanced potency and developability
See our AI drug creation process

Pipeline program partnerships

Absci is developing an internal biologics pipeline of potential first and best-in-class assets ready for partnering.

View our pipeline

Trusted by leading partners

astrazeneca_logo.svg_img
merck-part_img
almirall_logo_img
caltech-logo_img
Gates-Foundation-logo_img
nvidia_logo_image
twist-g6_image
pl-g-image
Oxford-University-img
astra-logo-slider

This collaboration is an exciting opportunity to utilize Absci's de novo AI antibody creation platform to design a potential new antibody therapy in oncology.

Puja Spara, PhD

Senior Vice President of Biologics Engineering & Oncology Targeted Delivery, AstraZeneca
merck-logo-slider

Absci falls into a special investment allocation towards what we see as 'Next Horizon' technologies that have the potential to disrupt the biopharmaceutical industry. Absci's technologies may enable discovery and development that could impact human health.

Prem Tumkosit

Managing Director, Merck Global Health Innovation Fund
nvidia-logo-slider

Absci's powerful data generation and AI protein engineering platform is already helping the drug discovery industry, and NVIDIA is excited to help power and scale Absci'sin silico technologies to achieve the best positive impact.

Kimberly Powell

Vice President of Healthcare, NVIDIA
precision-logo-slider

Our partnership demonstrates the transformational innovation potential of coupling leading generative AI approaches with PrecisionLife's unique disease biology insights.

Steve Gardner, PhD

CEO & Co-founder, PrecisionLife
almirall-logo-slider

Almirall chose Absci because their de novo platform brings truly novel innovation to the industry's most challenging targets with high unmet medical need.

Karl Ziegelbauer, PhD

Executive Vice President of R&D and Chief Scientific Officer, Almirall
Contact

Let's create together.

How can our Integrated Drug Creation™ platform help you go from drug discovery to drug creation?

Partner with us